Vericel Corporation (VCEL) shares plummeted 5.03% in Monday's trading session amid a price target cut by Truist Securities. The investment bank lowered its price target on the biopharmaceutical company's stock to $61 per share from the previous $67 target.
The downward revision in Vericel's price target by Truist Securities analysts appears to have weighed on investor sentiment, contributing to the sharp decline in the stock's price during Monday's intraday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.